Amphastar Pharmaceuticals, Inc.

AMPH

NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

Rancho Cucamonga, CA, US2,028 employeesamphastar.com

$20.44

+0.20(0.99%)

Mkt Cap $939M

$18.18

$30.81

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (96.1%), Product And Service Other (3.3%), Research And Development Services (0.6%).

8-K

On March 12, 2026, Amphastar Pharmaceuticals, Inc.’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, expected to continue for an indefinite period. The primary goal is to offset dilution created by the Company’s equity compensation programs, with purchases through open market, Rule 10b5-1 plans, or other means compliant with SEC requirements.

$939M

Market Cap

$721M

Revenue

$98M

Net Income

Employees2,028

Fundamentals

How The Business Makes Money

Revenue by Segment

Product96.1%($2.0B)

Product And Service Other3.3%($70M)

Research And Development Services0.6%($12M)

Revenue by Geography

US96.6%($2.0B)

FR2.9%($60M)

CN0.6%($12M)

Activity

What Changed Recently

Management Change

Mar 5, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On Marc

Material Agreement

Mar 5, 2026

. Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement. Supply Agreement. On March 3, 2026, (the “Effective Date”), Amp

Financial Results

Feb 25, 2026

. Results of Operations and Financial Condition. On February 26, 2026, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results

Material Agreement

Jan 11, 2026

. Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement. Material Definitive Agreement. On January 6, 2026, Amphastar Ph

Other Event

Mar 15, 2026

. Other Events On March 12, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected

Peer Companies

Company	Price	Change	Market Cap	P/E
SNDXSyndax Pharmaceuticals, I...	$25.08	+5.04%	$2.2B	-7.3
DVAXDVAX	$15.50	+0.00%	$1.8B	—
AHCOAdaptHealth Corp.	$12.04	+1.48%	$1.6B	-19.3
HROWHarrow Health, Inc.	$35.34	-0.25%	$1.3B	-243.2
CVACCVAC	$4.66	+0.00%	$1.0B	—
COLLCollegium Pharmaceutical,...	$32.27	-2.93%	$1.0B	17.5
PCRXPacira BioSciences, Inc.	$22.75	-0.20%	$979M	136.8
INBXInhibrx Biosciences, Inc.	$63.59	-5.17%	$929M	-7.1

Analyst View

Company Profile

CIK0001297184

ISINUS03209R1032

CUSIP03209R103

Phone909 980 9484

Address11570 6th Street, Rancho Cucamonga, CA, 91730, US

SEC EDGAR